Welcome to our dedicated page for Dianthus Therapeutics news (Ticker: DNTH), a resource for investors and traders seeking the latest updates and insights on Dianthus Therapeutics stock.
Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a clinical-stage biotechnology company that regularly reports on progress in its programs for severe autoimmune and inflammatory diseases. News about Dianthus often centers on clinical trial milestones, data readouts, licensing transactions, and capital markets activity related to its investigational therapies.
The company’s updates frequently highlight developments for claseprubart (DNTH103), an investigational monoclonal antibody targeting the classical complement pathway via active C1s inhibition, and DNTH212, an investigational bifunctional fusion protein targeting BDCA2 and BAFF/APRIL. Press releases describe Phase 2 and Phase 3 studies in neuromuscular indications such as generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy, as well as early-stage work in systemic lupus erythematosus through a Phase 1 trial of DNTH212.
Investors and followers of DNTH news can expect coverage of clinical data presentations at medical meetings, initiation and progress of Phase 1, Phase 2, and Phase 3 trials, and regulatory milestones such as investigational new drug clearances. Company communications also include announcements of public offerings of common stock and pre-funded warrants, license and collaboration agreements with partners like Nanjing Leads Biolabs, and participation in healthcare and investor conferences.
This news feed aggregates these disclosures so readers can track how Dianthus advances its investigational complement and immune pathway therapies, how its pipeline evolves, and how financing and partnerships support ongoing development. For those monitoring DNTH, recurring themes include neuromuscular disease programs, complement biology, bifunctional immune modulation, and the company’s positioning as a clinical-stage biotech focused on severe autoimmune conditions.
Dianthus Therapeutics (Nasdaq: DNTH) reported Q1 2026 results and program updates on May 5, 2026. Highlights include an early GO decision in the CAPTIVATE CIDP trial after 20 confirmed responders, FDA Orphan Drug Designation for claseprubart in Myasthenia Gravis, and a Phase 3 gMG trial on track to start in mid-2026 with top-line data expected in 2H'28.
Corporate: an upsized offering raised approximately $719 million, and cash totaled about $1.2 billion as of March 31, 2026, projected to provide runway into 2030. R&D and G&A rose; Q1 net loss was $40.8 million ($0.85 per share).
Dianthus Therapeutics (Nasdaq: DNTH) granted inducement equity awards on May 1, 2026 to six newly hired non-executive employees under Nasdaq Listing Rule 5635(c)(4). The grants total 135,000 non-qualified stock options with a 10-year term and an exercise price of $87.42 per share.
Options vest 25% after one year then monthly over 36 months and are governed by the company's Equity Inducement Plan and individual stock option agreements.
Dianthus Therapeutics (Nasdaq: DNTH) granted inducement equity awards on April 1, 2026, to eight newly hired, non‑executive employees under Nasdaq Listing Rule 5635(c)(4).
The awards are non‑qualified stock options for an aggregate of 135,000 shares, with a 10‑year term, $84.56 exercise price, and vesting of 25% after one year then monthly over 36 months; awards were approved by the independent Compensation Committee and are subject to the company equity inducement plan and option agreement.
Dianthus Therapeutics (Nasdaq: DNTH) closed an upsized underwritten public offering on March 12, 2026, raising approximately $719 million in aggregate gross proceeds before fees. The offering comprised 8,470,989 common shares (including 1,157,407 option shares) and pre-funded warrants to purchase 402,468 shares.
Pre-funded warrants were priced at $80.999 with a $0.001 exercise price and are exercisable immediately. Net proceeds will fund clinical and preclinical development, commercial readiness, working capital, and general corporate purposes.
Dianthus Therapeutics (Nasdaq: DNTH) priced an upsized underwritten public offering of 7,313,582 common shares at $81.00 per share and pre-funded warrants for 402,468 shares at $80.999, with aggregate gross proceeds of approximately $625 million before fees.
The offering is expected to close on March 12, 2026, and underwriters have a 30-day option to purchase up to an additional 1,157,407 shares. Net proceeds will fund clinical/preclinical programs, commercial readiness, working capital, and general corporate purposes.
Dianthus Therapeutics (Nasdaq: DNTH) announced a proposed underwritten public offering of $400 million of common stock or, for some investors, pre-funded warrants, with a 30-day underwriter option for up to $60 million additional shares. The offering is subject to market and other conditions.
Dianthus intends to use net proceeds to advance clinical and preclinical development, commercial readiness activities, and for working capital and general corporate purposes. Joint book-running managers include Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities and William Blair.
Dianthus Therapeutics (Nasdaq: DNTH) announced an early GO decision for the Phase 3 CAPTIVATE CIDP trial after achieving 20 confirmed responders with fewer than 40 participants completing open-label Part A. The company reported $514.4 million cash as of December 31, 2025, runway into 2028, full-year R&D of $145.6 million, and a 2025 net loss of $162.3 million. Key development timelines: gMG Phase 3 start mid-2026 (top-line 2H'28), MMN Phase 2 top-line 2H'26, and DNTH212 Phase 1 healthy volunteer data expected 2H'26.
Dianthus Therapeutics (Nasdaq: DNTH) announced an early GO decision in the Phase 3 CAPTIVATE trial of claseprubart for CIDP after an interim responder analysis met the predefined GO criterion.
The company reached 20 confirmed responders early, confirmed by an independent DSMB with no related serious infections or related serious adverse events. Planned updates include keeping the 300mg/2mL S.C. Q2W dose, seeking to remove the 600mg/4mL arm from Part B, reducing Part A enrollment to up to 256 patients (randomize 128 in Part B), and providing Part B top-line guidance by end of 2026.
Dianthus Therapeutics (Nasdaq: DNTH) will host a conference call and webcast on March 9, 2026 at 8:00 a.m. ET to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP.
Live access is available by phone with pre-registration and via the investor webcast at https://investor.dianthustx.com/. A replay will be posted following the call.
Dianthus Therapeutics (Nasdaq: DNTH) granted inducement equity awards on March 2, 2026 to three newly hired, non-executive employees.
The awards are non-qualified options for an aggregate of 26,000 shares, 10-year term, exercise price $55.26, vesting 25% after one year then monthly over 36 months.